Abstract
Stat-3 (Signal Transduction and Activator of Transcription) is a member of the Stat family of latent, cytosolic transcription factors that directly relate signals from the plasma membrane to the nucleus. This protein is constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human tumors, and it has been identified as a promising target for cancer drug discovery. This review deals with the recent developments of peptides and peptidomimetics or even non-peptidic small molecules, able to bind to the SH2 domain of Stat-3, thus blocking its functions. Moreover, several compounds able to alter the Stat-3 pathway by inhibition of kinases upstream to Stat-3, or even with unknown targets, were reviewed.
Keywords: Antitumor agents, Stat-3, Peptide-based antagonists, Small molecules, Natural compounds
Current Medicinal Chemistry
Title: STAT 3 as a Target for Cancer Drug Discovery
Volume: 15 Issue: 9
Author(s): Luca Costantino and Daniela Barlocco
Affiliation:
Keywords: Antitumor agents, Stat-3, Peptide-based antagonists, Small molecules, Natural compounds
Abstract: Stat-3 (Signal Transduction and Activator of Transcription) is a member of the Stat family of latent, cytosolic transcription factors that directly relate signals from the plasma membrane to the nucleus. This protein is constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human tumors, and it has been identified as a promising target for cancer drug discovery. This review deals with the recent developments of peptides and peptidomimetics or even non-peptidic small molecules, able to bind to the SH2 domain of Stat-3, thus blocking its functions. Moreover, several compounds able to alter the Stat-3 pathway by inhibition of kinases upstream to Stat-3, or even with unknown targets, were reviewed.
Export Options
About this article
Cite this article as:
Costantino Luca and Barlocco Daniela, STAT 3 as a Target for Cancer Drug Discovery, Current Medicinal Chemistry 2008; 15 (9) . https://dx.doi.org/10.2174/092986708783955464
DOI https://dx.doi.org/10.2174/092986708783955464 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Mass Spectrometry Based Proteomics for Interrogating the Histone Code
Current Proteomics Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Rho GTPase Activating Proteins in Cancer Phenotypes
Current Protein & Peptide Science Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Differential Proteomic Identification and Bioinformatics Analysis of Femoral Neck in Elderly Female Patients with Hyperuricaemia
Current Proteomics Telomerase Inhibition and Cancer: Might Platinum Based Drugs have a Future as Anti-telomerase Pharmacological Approach?
Current Medicinal Chemistry Reproducibility of Volumetric Assessment of the Inner Ear Using Three Dimensional Reconstruction of the High Resolution MR Sequence
Current Medical Imaging Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Anticancer Natural Compounds: Molecular Mechanisms and Functions. Part I)
Current Genomics APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery